Smith Michael David 4
4 · KalVista Pharmaceuticals, Inc. · Filed Feb 8, 2021
Insider Transaction Report
Form 4
Smith Michael David
Sr. VP, Development
Transactions
- Award
Stock Option (right to buy)
2021-02-07+16,500→ 16,500 totalExercise: $10.20Exp: 2030-06-16→ Common Stock (16,500 underlying)
Footnotes (1)
- [F1]Represents performance stock options granted to the Reporting Person on June 16, 2020. As a result of the Reporting Person having met the applicable performance criteria, 1/36 of the total stock options vests monthly over a 3-year period commencing on February 7, 2021 until fully vested, subject to the Reporting Person's continued service through each vesting date.